PITTSBURGH How a tiny marine invertebrate distinguishes its own cells from competitors bears striking similarities to the human immune system, according to a new study led by University of Pittsburgh School of Medicine researchers.
The findings, published now in Proceedings of the National Academy of Sciences, suggest that the building blocks of our immune system evolved much earlier than previously thought and could help improve understanding of transplant rejection, one day guiding development of new immunotherapies.
For decades, researchers have wondered whether self-recognition in a marine creature called Hydractinia symbiolongicarpus was akin to the processes that control whether a piece of skin can be successfully grafted from one person to another, said senior author Matthew Nictora, Ph.D., assistant professor of surgery and immunology at the Thomas E. Starzl Transplantation Institute. Our study shows for the first time that a special group of proteins called the immunoglobulin superfamily which are important for adaptive immunity in mammals and other vertebrates are found in such a distantly- related animal.
Hydractinia symbiolongicarpus belongs to the same group as jellyfish, corals and sea anemones. With tube-like bodies adorned with tentacles for catching prey, the animals look a bit like tiny versions of wacky inflatable tube men dancing outside of a car dealership. They grow as colonies encrusting the shells of hermit crabs like lichen on a rock.
As colonies grow and compete for space on crab shells, they often bump into each other, explained Nicotra, who is also associate director of the Center for Evolutionary Biology and Medicine in Pitts School of Medicine. If two colonies recognize each other as self, they fuse together. But if they identify each other as non-self, the colonies fight by releasing harpoon-like structures from special cells.
Nicotra and his colleagues previously identified two genes called Alr1 and Alr2 involved in Hydractinias fuse-or-fight system, but they predicted that there was more to the story.
If you imagine that the genome of the animal is spread out in front of us, we had a flashlight on these two little points, but we didnt know what else was there, said Nicotra. Now weve been able to sequence the whole genome and illuminate the whole region around these genes. It turns out that Alr1 and Alr2 are part of a huge family of genes.
In the new study, the researchers identified and sequenced 41 Alr genes, which form a complex that likely controls self- versus non-self-recognition in Hydractinia.
Next, the team wanted to see how the proteins that Alr genes encode compared to those found in vertebrates. Until recently, it was nearly impossible to accurately predict the 3D structure of proteins based on a genes sequence, but in 2021, the release of a tool called AlphaFold changed that.
Using this tool, the researchers compared the structure of Alr proteins to immunoglobulin superfamily (IgSF) proteins, an important group that includes antibodies and receptors on B and T cells of the immune system. IgSF proteins have three characteristic regions, or domains, including the V-set domain.
The V stands for variable, said Nicotra. When a B or T cell becomes specialized to fight a particular pathogen, V-set domains are rearranged to make a variable sequence, which the immune system uses to recognize specific pathogens or cells.
Nicotra was surprised to find that the domains in Alr proteins had 3D structures remarkably similar to V-set domains, even though they lacked telltale features usually found in IgSF proteins.
Unmistakably, these are V-set domains, he explained. Theyre just very, very strange.
Until now, it was thought that V-set domains had arisen in the branch of the animal kingdom known as Bilateria. This group originated about 540 million years ago and includes most familiar animals, including mammals, insects, fish, mollusks and all others with right and left sides.
The finding of V-set domains in Hydractinia which is part of a group that appeared earlier in the evolution of animals suggests that V-set domains arose further back in the evolutionary tree than previously thought.
Several Alr proteins also had signatures associated with immune signaling in other animals, another clue that this protein complex is involved in self-recognition.
We know lots about the immune systems of mammals and other vertebrates, but weve only scratched the surface of immunity in invertebrates, said Nicotra. We think that a better understanding of immune signaling in organisms like Hydractinia could ultimately point to alternative ways to manipulate those signaling pathways in patients with transplanted organs.
Other authors who contributed to the study were Aidan L. Huene, Ph.D., Steven M. Sanders, Ph.D., Zhiwei Ma, B.S., Manuel H. Michaca, B.S., all of Pitt; Anh-Dao Nguyen, Sergey Koren, Ph.D., Adam M. Phillippy, Ph.D., and Andreas D. Baxevanis, Ph.D., all of the National Human Genome Research Institute (NHGRI); James C. Mullikin, Ph.D., of the NHGRI and the National Institutes of Health (NIH); and Christine E. Schnitzler, Ph.D., of the University of Florida.
This research was funded by the National Science Foundation (1557339 and 1923259) and the NIH (ZIA HG000140, ZIA HG200398 andT32 AI074490).
PHOTO DETAILS: (click images for high-res versions)
CREDIT: Matthew Nictora
CAPTION:Matthew Nictora, Ph.D., assistant professor of surgery and immunology at the University of Pittsburgh Thomas E. Starzl Transplantation Institute and associate director of the Center for Evolutionary Biology and Medicine.
PHOTO DETAILS: (click images for high-res versions)
CREDIT:Huene, A. L. et al., PNAS, 2022
CAPTION:When compatible Hydractinia symbiolongicarpus colonies recognize each other as self, via Alr genes, they fuse together.
PHOTO DETAILS: (click images for high-res versions)
CREDIT:Huene, A. L. et al., PNAS, 2022
CAPTION:When incompatible Hydractinia symbiolongicarpus colonies identify each other as non-self via Alr genes, they fight. As a result, the colony on the left has started to grow over the colony on the right.
Follow this link:
Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022
- Study refutes long-held belief that the Corin gene causes hypertension in African Americans - University of Alabama at Birmingham - September 14th, 2022
- Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss - Yahoo... - September 14th, 2022
- Solving medical mysteries with genetics: The Penn Neurogenetics Therapy Center | Penn Today - Penn Today - September 14th, 2022
- Pharmacogenetics Testing in Psychiatry/Depression Market Will Rise at a CAGR 9.5% by 2029 and is segmented by Test Type, Gene Type, Patient Type,... - September 14th, 2022
- Scientists have created a mathematical model for the dynamics of nanoparticles and viruses in cells - EurekAlert - September 14th, 2022
- Fierce Biotech Names ReCode Therapeutics as One of its Fierce 15 Biotech Companies of 2022 - Business Wire - September 14th, 2022
- Foundation Medicine, Relay Therapeutics to Develop FoundationOne CDx for FGFR2 Inhibitor - GenomeWeb - September 14th, 2022
- Downstream Processing in the Age of Precision Medicine: Trends and Challenges - Technology Networks - September 14th, 2022
- BU receives NIH award to increase diversity of STEM and biomedical science workforce - EurekAlert - September 14th, 2022
- Leveraging Best-of-Breed Algorithms for Accuracy in Precision Medicine - BioSpace - September 14th, 2022